Chronic urotensin II receptor antagonist treatment does not alter hypertrophy or fibrosis in a rat model of pressure-overload hypertrophy

Peptides

Volumn 31, Issue 8, 2010, Pages 1523-1530

  Kompa, Andrew R ^a,b   Wang, Bing H ^a   Phrommintikul, Arintaya ^a,d   Ho, Pei Y ^a   Kelly, Darren J ^b   Behm, David J ^c   Douglas, Stephen A ^c   Krum, Henry ^a  

^a MONASH UNIVERSITY   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c GLAXOSMITHKLINE   (United States)

^d Faculty of Medicine Chiang Mai University   (Thailand)

Author keywords

Cardiac fibrosis; Cardiac function; Echocardiography; Left ventricular hypertrophy; Pressure overload hypertrophy; Urotensin II receptor antagonist

Indexed keywords

2 BROMO N [4 CHLORO 3 (1 METHYLPYRROLIDIN 3 YLOXY)PHENYL] 4,5 DIMETHOXYBENZENESULFONAMIDE; COLLAGEN TYPE 1; COLLAGEN TYPE 2; MITOGEN ACTIVATED PROTEIN KINASE; SB 657510; UNCLASSIFIED DRUG; UROTENSIN II; UROTENSIN RECEPTOR ANTAGONIST;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA CONSTRICTION; ARTICLE; BODY WEIGHT; CARDIOVASCULAR PARAMETERS; CONTROLLED STUDY; DIASTOLIC DYSFUNCTION; DRUG EFFECT; ECHOCARDIOGRAPHY; ENZYME PHOSPHORYLATION; FIBROBLAST; HEART FUNCTION; HEART HEMODYNAMICS; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE OVERLOAD; HEART MUSCLE; HEART MUSCLE FIBROSIS; MALE; NONHUMAN; ORGAN WEIGHT; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SYSTOLIC DYSFUNCTION;

ANIMALIA; RATTUS;

EID: 78249263484     PISSN: 01969781     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.peptides.2010.04.026     Document Type: Article

References (35)

1. Akers WS, Cross A, Speth R, Dwoskin LP, Cassis LA. Renin-angiotensin system and sympathetic nervous system in cardiac pressure-overload hypertrophy. Am J Physiol Heart Circ Physiol 2000; 279:H2797-806.
2. Ames RS, Sarau HM, Chambers JK, Willette RN, Aiyar NV, Romanic AM, et al. Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14. Nature 1999; 401:282-286
3. Behm DJ, McAtee JJ, Dodson JW, Neeb MJ, Fries HE, Evans CA, et al. Palosuran inhibits binding to primate UT receptors in cell membranes but demonstrates differential activity in intact cells and vascular tissues. Br J Pharmacol 2008; 155:374-386
4. Bousette N, Hu F, Ohlstein EH, Dhanak D, Douglas SA, Giaid A. Urotensin-II blockade with SB-611812 attenuates cardiac dysfunction in a rat model of coronary artery ligation. J Mol Cell Cardiol 2006; 41:285-295
5. Bousette N, Pottinger J, Ramli W, Ohlstein EH, Dhanak D, Douglas SA, et al. Urotensin-II receptor blockade with SB-611812 attenuates cardiac remodeling in experimental ischemic heart disease. Peptides 2006; 27:2919-2926
6. Cheung BM, Leung R, Man YB, Wong LY. Plasma concentration of urotensin II is raised in hypertension. J Hypertens 2004; 22:1341-1344
7. Douglas SA, Behm DJ, Aiyar NV, Naselsky D, Disa J, Brooks DP, et al. Nonpeptidic urotensin-II receptor antagonists I: in vitro pharmacological characterization of SB-706375. Br J Pharmacol 2005; 145:620-635
8. Douglas SA, Tayara L, Ohlstein EH, Halawa N, Giaid A. Congestive heart failure and expression of myocardial urotensin II. Lancet 2002; 359:1990-1997
9. Ganguly PK, Dhalla KS, Shao Q, Beamish RE, Dhalla NS. Differential changes in sympathetic activity in left and right ventricles in congestive heart failure after myocardial infarction. Am Heart J 1997; 133:340-345
10. Harris GS, Lust RM, Katwa LC. Hemodynamic effects of chronic urotensin II administration in animals with and without aorto-caval fistula. Peptides 2007; 28:1483-1489
11. Hirose T, Takahashi K, Mori N, Nakayama T, Kikuya M, Ohkubo T, et al. Increased expression of urotensin II, urotensin II-related peptide and urotensin II receptor mRNAs in the cardiovascular organs of hypertensive rats: comparison with endothelin-1. Peptides 2009; 30:1124-1129
12. Hirsch AT, Opsahl JA, Lunzer MM, Katz SA. Active renin and angiotensinogen in cardiac interstitial fluid after myocardial infarction. Am J Physiol 1999; 276:H1818-26.
13. Kompa AR, See F, Lewis DA, Adrahtas A, Cantwell DM, Wang BH, et al. Long-term but not short-term p38 mitogen-activated protein kinase inhibition improves cardiac function and reduces cardiac remodeling post-myocardial infarction. J Pharmacol Exp Ther 2008; 325:741-750
14. Kompa AR, Thomas WG, See F, Tzanidis A, Hannan RD, Krum H. Cardiovascular role of urotensin II: effect of chronic infusion in the rat. Peptides 2004; 25:1783-1788
15. Kurosawa Y, Katoh M, Doi H, Narita H. Tissue angiotensin-converting enzyme activity plays an important role in pressure overload-induced cardiac fibrosis in rats. J Cardiovasc Pharmacol 2002; 39:600-609
16. Lim M, Honisett S, Sparkes CD, Komesaroff P, Kompa A, Krum H. Differential effect of urotensin II on vascular tone in normal subjects and patients with chronic heart failure. Circulation 2004; 109:1212-1214
17. Maguire JJ, Kuc RE, Wiley KE, Kleinz MJ, Davenport AP. Cellular distribution of immunoreactive urotensin-II in human tissues with evidence of increased expression in atherosclerosis and a greater constrictor response of small compared to large coronary arteries. Peptides 2004; 25:1767-1774
18. Mukawa H, Toki Y, Miyazaki Y, Matsui H, Okumura K, Ito T. Angiotensin II type 2 receptor blockade partially negates antihypertrophic effects of type 1 receptor blockade on pressure-overload rat cardiac hypertrophy. Hypertens Res 2003; 26:89-95.
19. Nakayama T, Hirose T, Totsune K, Mori N, Maruyama Y, Maejima T, et al. Increased gene expression of urotensin II-related peptide in the hearts of rats with congestive heart failure. Peptides 2008; 29:801-808
20. Papadopoulos P, Bousette N, Al-Ramli W, You Z, Behm DJ, Ohlstein EH, et al. Targeted overexpression of the human urotensin receptor transgene in smooth muscle cells: effect of UT antagonism in ApoE knockout mice fed with Western diet. Atherosclerosis 2009; 204:395-404.
21. Phrommintikul A, Tran L, Kompa A, Wang B, Adrahtas A, Cantwell D, et al. Effects of a Rho kinase inhibitor on pressure overload induced cardiac hypertrophy and associated diastolic dysfunction. Am J Physiol Heart Circ Physiol 2008; 294:H1804-14.
22. Richards AM, Nicholls MG, Lainchbury JG, Fisher S, Yandle TG. Plasma urotensin II in heart failure. Lancet 2002; 360:545-546
23. Salemi VM, Pires MD,Cestari IN, Cestari IA, Picard MH,Leirner AA, et al. Echocardiographic assessment of global ventricular function using the myocardial performance index in rats with hypertrophy. Artif Organs 2004; 28:332-337
24. Schiller NB, Shah PM, Crawford M, DeMaria A, Devereux R, Feigenbaum H, et al. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. J Am Soc Echocardiogr 1989; 2:358-367
25. Shimada Y, Avkiran M. Left and right coronary circulation in left ventricular hypertrophy: effects of angiotensin converting enzyme inhibition. Circ J 2002; 66:1168-1172
26. Silver MA, Pick R, Brilla CG, Jalil JE, Janicki JS, Weber KT. Reactive and reparative fibrillar collagen remodelling in the hypertrophied rat left ventricle: two experimental models of myocardial fibrosis. Cardiovasc Res 1990; 24:741-747
27. Sondermeijer B, Kompa A, Komesaroff P, Krum H. Effect of exogenous urotensin-II on vascular tone in skin microcirculation of patients with essential hypertension. Am J Hypertens 2005; 18:1195-1199
28. Sugo T, Murakami Y, Shimomura Y, Harada M, Abe M, Ishibashi Y, et al. Identification of urotensin II-related peptide as the urotensin II-immunoreactive molecule in the rat brain. Biochem Biophys Res Commun 2003; 310:860-868
29. Tamura K, Okazaki M, Tamura M, Isozumi K, Tasaki H, Nakashima Y. Urotensin II-induced activation of extracellular signal-regulated kinase in cultured vascular smooth muscle cells: involvement of cell adhesion-mediated integrin signaling. Life Sci 2003; 72:1049-1060
30. Tonnessen T, Lunde PK, Giaid A, Sejersted OM, Christensen G. Pulmonary and cardiac expression of preproendothelin-1 mRNA are increased in heart failure after myocardial infarction in rats. Localization of preproendothelin-1 mRNA and endothelin peptide. Cardiovasc Res 1998; 39:633-643
31. Totsune K, Takahashi K, Arihara Z, Sone M, Ito S, Murakami O. Increased plasma urotensin II levels in patients with diabetes mellitus. Clin Sci (Lond) 2003; 104:1-5.
32. Tran L, Kompa AR, Kemp W, Phrommintikul A, Wang BH, Krum H. Chronic urotensin-II infusion induces diastolic dysfunction and enhances collagen production in rats. Am J Physiol Heart Circ Physiol 2010; 298:H608-13.
33. Tzanidis A, Hannan RD, Thomas WG, Onan D, Autelitano DJ, See F, et al. Direct actions of urotensin II on the heart: implications for cardiac fibrosis and hypertrophy. Circ Res 2003; 93:246-253
34. Woodiwiss AJ, Tsotetsi OJ, Sprott S, Lancaster EJ, Mela T, Chung ES, et al. Reduction in myocardial collagen cross-linking parallels left ventricular dilatation in rat models of systolic chamber dysfunction. Circulation 2001; 103:155-160
35. Zou Y, Nagai R, Yamazaki T. Urotensin II induces hypertrophic responses in cultured cardiomyocytes from neonatal rats. FEBS Lett 2001; 508:57-60.